The pan-histone deacetylase inhibitor CR2408 disrupts cell cycle progression, diminishes proliferation and causes apoptosis in multiple myeloma cells

British Journal of Haematology

Volumn 156, Issue 5, 2012, Pages 633-642

  Baumann, Philipp ^a   Junghanns, Carmen ^a   Mandl Weber, Sonja ^a   Strobl, Stefan ^b   Oduncu, Fuat ^a   Schmidmaier, Ralf ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b 4SC AG   (Germany)

Author keywords

Apoptosis; Cell cycle; CR2408; Histone deacetylase; Multiple myeloma

Indexed keywords

BIM PROTEIN; BORTEZOMIB; CASPASE 3; CASPASE 8; CASPASE 9; CR 2408; CYCLIN D1; CYCLIN DEPENDENT KINASE 4; DOXORUBICIN; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HISTONE H4; INITIATION FACTOR 4E BINDING PROTEIN 1; PROTEIN BAD; PROTEIN BCL XL; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; RETINOBLASTOMA PROTEIN; S6 KINASE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GROWTH INHIBITION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INHIBITION KINETICS; MULTIPLE MYELOMA; PRIORITY JOURNAL;

ACETYLATION; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL CYCLE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; MULTIPLE MYELOMA; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; PYRROLES; SIGNAL TRANSDUCTION; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84857034491     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08983.x     Document Type: Article

References (42)

1. Badros, A., Burger, A.M., Philip, S., Niesvizky, R., Kolla, S.S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J.J., Espinoza-Delgado, I., Baer, M.R., Holleran, J.L., Egorin, M.J. & Grant, S. (2009) Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clinical Cancer Research, 15, 5250-5257.
2. Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R. & Crowley, J. (2004) Treatment of multiple myeloma. Blood, 103, 20-32.
3. Batty, N., Malouf, G.G. & Issa, J.P. (2009) Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Letters, 280, 192-200.
4. Bolden, J.E., Peart, M.J. & Johnstone, R.W. (2006) Anticancer activities of histone deacetylase inhibitors. Nature Reviews. Drug Discovery, 5, 769-784.
5. Catley, L., Weisberg, E., Tai, Y.T., Atadja, P., Remiszewski, S., Hideshima, T., Mitsiades, N., Shringarpure, R., LeBlanc, R., Chauhan, D., Munshi, N.C., Schlossman, R., Richardson, P., Griffin, J. & Anderson, K.C. (2003) NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood, 102, 2615-2622.
6. Dasmahapatra, G., Lembersky, D., Kramer, L., Fisher, R.I., Friedberg, J., Dent, P. & Grant, S. (2010) The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood, 115, 4478-4487.
7. De Nadal, E., Zapater, M., Alepuz, P.M., Sumoy, L., Mas, G. & Posas, F. (2004) The MAPK Hog1 recruits Rpd3 histone deacetylase to activate osmoresponsive genes. Nature, 427, 370-374.
8. Deleu, S., Lemaire, M., Arts, J., Menu, E., Van Valckenborgh, E., King, P., Vande Broek, I., De Raeve, H., Van Camp, B., Croucher, P. & Vanderkerken, K. (2009a) The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models. Leukemia, 23, 1894-1903.
9. Deleu, S., Lemaire, M., Arts, J., Menu, E., Van Valckenborgh, E., Vande Broek, I., De Raeve, H., Coulton, L., Van Camp, B., Croucher, P. & Vanderkerken, K. (2009b) Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma. Cancer Research, 69, 5307-5311.
10. Fabre, C., Grosjean, J., Tailler, M., Boehrer, S., Ades, L., Perfettini, J.L., de Botton, S., Fenaux, P. & Kroemer, G. (2008) A novel effect of DNA methyltransferase and histone deacetylase inhibitors: NFkappaB inhibition in malignant myeloblasts. Cell Cycle, 7, 2139-2145.
11. Feng, R., Oton, A., Mapara, M.Y., Anderson, G., Belani, C. & Lentzsch, S. (2007) The histone deacetylase inhibitor, PXD101, potentiates bortezomib-induced anti-multiple myeloma effect by induction of oxidative stress and DNA damage. British Journal of Haematology, 139, 385-397.
12. Feng, R., Ma, H., Hassig, C.A., Payne, J.E., Smith, N.D., Mapara, M.Y., Hager, J.H. & Lentzsch, S. (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling. Molecular Cancer Therapeutics, 7, 1494-1505.
13. Fraga, M.F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., Iyer, N.G., Perez-Rosado, A., Calvo, E., Lopez, J.A., Cano, A., Calasanz, M.J., Colomer, D., Piris, M.A., Ahn, N., Imhof, A., Caldas, C., Jenuwein, T. & Esteller, M. (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nature Genetics, 37, 391-400.
14. Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N. & Rambaldi, A. (2009) A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma. Annals of Hematology, 89, 185-190.
15. Gupta, M., Ansell, S.M., Novak, A.J., Kumar, S., Kaufmann, S.H. & Witzig, T.E. (2009) Inhibition of histone deacetylase overcomes rapamycin- mediated resistance in diffuse large B cell lymphoma by inhibiting Akt signaling through mTORC2. Blood, 114, 2926-2935.
16. Kaiser, M., Zavrski, I., Sterz, J., Jakob, C., Fleissner, C., Kloetzel, P.M., Sezer, O. & Heider, U. (2006) The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica, 91, 248-251.
17. Khan, S.B., Maududi, T., Barton, K., Ayers, J. & Alkan, S. (2004) Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma. British Journal of Haematology, 125, 156-161.
18. Kitazoe, K., Abe, M., Hiasa, M., Oda, A., Amou, H., Harada, T., Nakano, A., Takeuchi, K., Hashimoto, T., Ozaki, S. & Matsumoto, T. (2009) Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma. International Journal of Hematology, 89, 45-57.
19. Lane, D.P. (1992) Cancer. p53, guardian of the genome. Nature, 358, 15-16.
20. Lavelle, D., Chen, Y.H., Hankewych, M. & DeSimone, J. (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. American Journal of Hematology, 68, 170-178.
21. Maiso, P., Carvajal-Vergara, X., Ocio, E.M., Lopez-Perez, R., Mateo, G., Gutierrez, N., Atadja, P., Pandiella, A. & San Miguel, J.F. (2006) The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Research, 66, 5781-5789.
22. Mandl-Weber, S., Meinel, F.G., Jankowsky, R., Oduncu, F., Schmidmaier, R. & Baumann, P. (2010) The novel inhibitor of histone deacetylase resminostat (RAS2410) inhibits proliferation and induces apoptosis in multiple myeloma (MM) cells. British Journal of Haematology, 149, 518-528.
23. Marsoni, S., Damia, G. & Camboni, G. (2008) A work in progress: the clinical development of histone deacetylase inhibitors. Epigenetics, 3, 164-171.
24. Mitsiades, C.S., Mitsiades, N.S., McMullan, C.J., Poulaki, V., Shringarpure, R., Hideshima, T., Akiyama, M., Chauhan, D., Munshi, N., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Richon, V.M., Marks, P.A. & Anderson, K.C. (2004) Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 101, 540-545.
25. Mitsiades, C.S., Hideshima, T., Chauhan, D., McMillin, D.W., Klippel, S., Laubach, J.P., Munshi, N.C., Anderson, K.C. & Richardson, P.G. (2009) Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Seminars in Hematology, 46, 166-175.
26. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., McMullan, C., Poulaki, V., Fanourakis, G., Schlossman, R., Chauhan, D., Munshi, N.C., Hideshima, T., Richon, V.M., Marks, P.A. & Anderson, K.C. (2003) Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood, 101, 4055-4062.
27. Neri, P., Tagliaferri, P., Di Martino, M.T., Calimeri, T., Amodio, N., Bulotta, A., Ventura, M., Eramo, P.O., Viscomi, C., Arbitrio, M., Rossi, M., Caraglia, M., Munshi, N.C., Anderson, K.C. & Tassone, P. (2008) In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. British Journal of Haematology, 143, 520-531.
28. Pei, X.Y., Dai, Y. & Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research, 10, 3839-3852.
29. Raab, M.S., Podar, K., Breitkreutz, I., Richardson, P.G. & Anderson, K.C. (2009) Multiple myeloma. Lancet, 374, 324-339.
30. Richardson, P., Mitsiades, C., Colson, K., Reilly, E., McBride, L., Chiao, J., Sun, L., Ricker, J., Rizvi, S., Oerth, C., Atkins, B., Fearen, I., Anderson, K. & Siegel, D. (2008) Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leukaemia & Lymphoma, 49, 502-507.
31. Roussel, M.F. (1999) The INK4 family of cell cycle inhibitors in cancer. Oncogene, 18, 5311-5317.
32. Sarbassov, D.D., Ali, S.M. & Sabatini, D.M. (2005) Growing roles for the mTOR pathway. Current Opinion in Cell Biology, 17, 596-603.
33. Sharma, V., Koul, N., Joseph, C., Dixit, D., Ghosh, S. & Sen, E. (2010) HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. Journal of Cellular and Molecular Medicine, 14, 2151-2161.
34. Siegel, D., Weber, D., Mitsiades, C.S., Rizvi, S., Garcia-Vargas, J., Howe, J., Reiser, D., Anderson, K.C. & Richardson, P. (2008) A Phase I Study of Vorinostat in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma. Blood (ASH Annual Meeting Abstracts), 112, 3705.
35. Tang, Y., Zhao, W., Chen, Y., Zhao, Y. & Gu, W. (2008) Acetylation is indispensable for p53 activation. Cell, 133, 612-626.
36. Villar-Garea, A. & Esteller, M. (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. International Journal of Cancer, 112, 171-178.
37. Wang, A., Kurdistani, S.K. & Grunstein, M. (2002) Requirement of Hos2 histone deacetylase for gene activity in yeast. Science, 298, 1412-1414.
38. Weber, D., Badros, A.Z., Jagannath, S., Siegel, D., Richon, V., Rizvi, S., Garcia-Vargas, J., Reiser, D. & Anderson, K.C. (2008a) Vorinostat Plus Bortezomib for the Treatment of Relapsed/Refractory Multiple Myeloma: early Clinical Experience. Blood (ASH Annual Meeting Abstracts), 112, 871.
39. Weber, D.M., Jagannath, S., Sobecks, R., Schiller, G., Chiacchierini, L., Reiser, D., Oerth, C., Garcia-Vargas, J. & Rizvi, S. (2008b) Combination of Vorinostat Plus Bortezomib for the Treatment of Patients with Multiple Myeloma Who Have Previously Received Bortezomib. Blood (ASH Annual Meeting Abstracts), 112, 3711.
40. Wegener, D., Wirsching, F., Riester, D. & Schwienhorst, A. (2003) A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chemistry and Biology, 10, 61-68.
41. Zhang, S., Suvannasankha, A., Crean, C.D., White, V.L., Chen, C.S. & Farag, S.S. (2010) The novel histone deacetylase inhibitor, AR-42, inhibits gp130/Stat3 pathway and induces apoptosis and cell cycle arrest in multiple myeloma cells. International Journal of Cancer, 129, 204-213.
42. Zollinger, A., Stuhmer, T., Chatterjee, M., Gattenlohner, S., Haralambieva, E., Muller-Hermelink, H.K., Andrulis, M., Greiner, A., Wesemeier, C., Rath, J.C., Einsele, H. & Bargou, R.C. (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood, 112, 3403-3411.